THEO-260 injection for ovarian cancer patients
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests an investigational drug called THEO-260, given directly into the belly (intraperitoneal), for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum chemotherapy. The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced high-grade serous or endometrioid cancer of the ovary, fallopian tube, or peritoneum (confirmed by biopsy).
- Your cancer must be platinum-resistant or platinum-refractory (progressed within 6 months of platinum treatment or within 3 months of starting it).
- You must be well enough to be up and about (ECOG score 0 or 1) and have a life expectancy of more than 6 months.
- You must have tumors that can be measured on scans (RECIST criteria).
- You must not have had a bowel obstruction in the last 3 months or any signs of one now.
- You cannot have certain other health conditions such as uncontrolled fluid in the chest or belly, certain heart rhythm problems, active infections (including HIV, hepatitis, or tuberculosis), or a history of lung inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new virus-based medicine called THEO-260 for people with a certain type of ovarian cancer that no longer responds to standard platinum chemo. The goal is to see if this treatment can shrink tumors or slow the cancer down.
This study tests a new drug called TUB-040 for people with ovarian cancer that has stopped responding to platinum chemotherapy, or with a type of lung cancer that has returned or spread. The drug is designed to target cancer cells and deliver a powerful anti-cancer agent directly to them, potentially slowing the disease.
This study tests a new medicine called TUB-040, given together with standard ovarian cancer drugs like carboplatin and bevacizumab. It is for women with ovarian cancer that has returned after responding to platinum-based chemotherapy and is growing again. The goal is to see if this combination can help control the cancer.
This trial tests a new combination of treatments for advanced ovarian, fallopian tube, or peritoneal cancer. It combines chemotherapy and immunotherapy (drugs that help your immune system fight cancer) with a special vaccine made from your own tumor. The goal is to see if this approach is more effective than standard treatment.
This trial is testing a new drug, LBL-024, combined with chemotherapy (with or without a targeted therapy called bevacizumab) for ovarian cancer that has stopped responding to standard platinum-based treatment. The goal is to see if this combination can effectively shrink tumors and slow the disease's progression.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.